Correct, I was asleep! But I did watch the MOA discussion from the ODAC meeting this morning. The MSB response reiterated that they clearly believe this therapy is not just a treatment for SR-aGVHD, but a treatment for a wide range of diseases involving systemic inflammation.
My point is that whether the MOA is, in fact, generalisable to other clinical applications beyond SR-aGVHD will have to be borne out in further clinical trials involving the treatment of other diseases. MSB have me convinced, and I desperately hope the results of future clinical trials for other applications (incl. for C-19-related ARDS) continue to support the theorised MOA!
MSB Trading 2020 - a new dawn, page-559
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
-0.210(11.8%) |
Mkt cap ! $1.792B | |||
| Open | High | Low | Value | Volume |
| $1.72 | $1.74 | $1.52 | $15.63M | 9.716M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5127 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.57 | 39613 | 3 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |